Cocrystal Pharma (COCP) FCF Margin (2010 - 2026)

Cocrystal Pharma (COCP) reported FCF Margin of 1040.0% for Q1 2026, down 122.67% sequentially from 467.06% in Q4 2020.

Cocrystal Pharma (COCP) FCF Margin (2010 - 2026) Analysis & Trends

Cocrystal Pharma (COCP) has 7 years of FCF Margin data on file, last reported at 1040.0% in Q1 2026.

For the quarter ending Q1 2026, FCF Margin changed N/A year-over-year to 1040.0%; the trailing twelve-month figure through Mar 2026 stood at 427.5% (changed N/A YoY), and the FY2020 full-year result was 500.0%, down 47398.0% from the prior year.
FCF Margin fell to 1040.0% in Q1 2026, from 467.06% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1040.0% in Q1 2026 to a low of 1040.0% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	10.45%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	23.53%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-	-1,040.00%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-1,040.00%
Dec 31, 2020	-467.06%
Sep 30, 2020	-629.86%
Jun 30, 2020	-420.04%
Mar 31, 2020	-494.79%
Dec 31, 2019	-306.22%
Sep 30, 2019	-292.28%
Jun 30, 2019	-174.32%
Mar 31, 2019	39.25%
Jun 30, 2013	-34.90%
Mar 31, 2013	2.71%
Dec 31, 2012	5.57%
Sep 30, 2012	7.33%
Jun 30, 2012	-2.80%
Mar 31, 2012	-62.05%
Dec 31, 2011	-21.76%
Sep 30, 2011	16.82%
Jun 30, 2011	-14.49%
Mar 31, 2011	-17.41%
Dec 31, 2010	2.91%